Unless there’s strong evidence, use of HCQ should not be scaled up: Sanjay Pujari

HCQ may be good for compassionate use on a case-to-case basis depending on the physician’s discretion. I don’t think we should scale it up to treat everybody unless there is strong evidence from a well-designed trial, says Sanjay Pujari, part of the National Task Force on Clinical Research of Covid-19 and director, Institute of Infectious Diseases, Pune.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/34NlDKW
via IFTTT